Heron Therapeutics, Inc. — Form 8-K Summary
Report date: September 23, 2026. The filing reports a material agreement; it does not report quarterly or annual financial results.
Business context
On September 23, 2026, Heron entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC.
Heron received an exclusive, sublicensable license, as to the licensed patents, to import, distribute, sell, and market certain products in the United States and its territories. It also received a non-exclusive worldwide manufacturing license for products sold in that territory. The parties have specified collaboration obligations for development and commercialization. Capstone provides certain exclusivity covenants and backstop obligations.
Financial metrics and agreement economics
The filing gives no revenue, profit, cash flow, margin, debt, or liquidity figures. Heron must pay Long Grove regulatory and sales-based milestone payments and royalties, and reimburse certain expenses. The amounts, rates, timing, and potential maximum obligations are not stated in this filing.
Changes, outlook, and risks
No comparison with a prior period or quantified financial outlook is provided. The agreement has an initial term of ten years following the first commercial sale of any product, with automatic two-year renewals. Either party may terminate upon specified customary conditions. The filing does not provide product-specific development milestones, launch timing, sales expectations, or detailed termination conditions.
Important facts to verify
- Review the full License Agreement, which Heron said it would file as an exhibit to its Form 10-Q for the quarter ending September 30, 2026.
- Confirm the products covered, regulatory and development responsibilities, and any exclusivity limitations.
- Assess the milestone, royalty, and expense-reimbursement terms and their potential effect on cash flows and profitability.
- Verify termination rights, renewal provisions, and the status and timing of development and commercialization.